Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A Completed N=245 Randomized Single-blind Supportive Care

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

HIV
Source: ClinicalTrials.gov NCT03331978 ↗
Enrolled (actual)
245
Serious AEs
0.0%
Results posted
Jan 2023
Primary outcomePrimary: Continuous Adherence — 68.80; 70.95; 72.76; 70.02 percentage of doses taken — p=.08

Summary

Project Rise is a randomized controlled trial (RCT) of an innovative, culturally congruent treatment education (TE) intervention for African Americans with HIV that targets cultural and social issues contributing to health disparities.

Outcome Measures

OutcomeResultp-value
PRIMARY
Continuous Adherence		 68.80; 70.95; 72.76; 70.02; 72.09; 64.62 .08
PRIMARY
Dichotomous Adherence		 45; 43; 44; 40; 43; 38 .0257 sig
PRIMARY
Viral Suppression		 45; 60; 50; 56 .26
SECONDARY
Internalized HIV Stigma		 25; 29; 15; 26 .05
SECONDARY
Medical Mistrust		 2.62; 2.65; 2.41; 2.56 .0199 sig

Eligibility Criteria

Inclusion Criteria

  • HIV-positive
  • 18 years of age or older
  • Self-identified as African American/Black
  • Been prescribed antiretroviral therapy (ART) in the past 12 months
  • Self-reported adherence problems (i.e. missed at least 1 ART dose in the past month) and/or detectable viral load
  • Willing to use Medication Events Monitoring System (MEMS) for electronic adherence monitoring.

Exclusion Criteria

  • HIV-negative
  • 17 years of age or younger
  • Not self-identified as African American/Black, not on antiretroviral therapy (ART) or not prescribed ART therapy in the last than 12 months
  • No self-reported adherence problems and/or no detectable viral load
  • Not willing to use Medication Events Monitoring System (MEMS) for electronic adherence monitoring.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03331978). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search